Rapport Therapeutics (RAPP) Operating Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Operating Expenses for 4 consecutive years, with $44.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 63.11% year-over-year to $44.2 million; the TTM figure through Mar 2026 stood at $142.2 million (up 52.8% YoY), while the FY2025 annual figure was $125.1 million, up 50.62% from the prior year.
• Operating Expenses grew to $44.2 million in Q1 2026 per RAPP's latest filing, from $38.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $44.2 million in Q1 2026 and bottomed at $6.6 million in Q2 2023.
• Historically, Operating Expenses has averaged $23.6 million across 4 years, with a median of $22.6 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Expenses jumped 213.73% — and 2025, when it soared 38.57%.
• Rapport Therapeutics' Operating Expenses stood at $14.8 million in 2023, then soared by 58.99% to $23.5 million in 2024, then surged by 63.72% to $38.5 million in 2025, then rose by 14.82% to $44.2 million in 2026.
• Business Quant data shows RAPP's Operating Expenses at $44.2 million in Q1 2026, $38.5 million in Q4 2025, and $30.0 million in Q3 2025.